Potential of carrageenans to protect drugs from polymorphic transformation

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 56, Issue 1, 2003, Pages 101-110

  Schmidt, Andrea G ^a   Wartewig, Siegfried ^a   Picker, Katharina M ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Carrageenan; Dehydration; Excipient; FT Raman spectroscopy; Indomethacin; Polymorphic transition; Recrystallisation; Tableting; Theophylline; Three dimensional modelling

Indexed keywords

CALCIUM PHOSPHATE DIBASIC; CARRAGEENAN; HYDROXYPROPYLMETHYLCELLULOSE; INDOMETACIN; MICROCRYSTALLINE CELLULOSE; THEOPHYLLINE;

ARTICLE; DENSITY; DRUG TRANSFORMATION; MODEL; RAMAN SPECTROMETRY; TABLET MANUFACTURE; THERMAL ANALYSIS;

EID: 0038015537     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-6411(03)00037-7     Document Type: Article

References (41)

1. Borka L. Review on crystal polymorphism of substances in the European Pharmacopeia. Pharm. Acta Helv. 66:(1):1991;16-22.
2. Brittain H.G., Fiese E.F. Effects of pharmaceutical processing on drug polymorphs and solvates. Brittain H.G. Polymorphism in Pharmaceutical Solids. 1999;348-361 Marcel Dekker Inc, New York, Basel.
3. Ibrahim H.G., Pisano F., Bruno A. Polymorphism of phenylbutazone: properties and compressional behavior of crystal. J. Pharm. Sci. 66:(5):1977;669-673.
4. Kala H., Traue J., Haack U., Moldenhauer H., Kedvessy G., Selmeczi B. Zur Zeitabhängigkeit der Modifikationsumwandlung des Sulfanilamids bei der Tablettenkompression. Pharmazie. 37:(9):1982;674-675.
5. Chan H.K., Doelker E. Polymorphic transformation of some drugs under compression. Drug Dev. Ind. Pharm. 11:(2/3):1985;315-332.
6. Otsuka M., Matsuda Y. Polymorphism: pharmaceutical aspects. Swarbrick J., Boylan J.C. Encyclopedia of Pharmaceutical Technology. 1988;305-326 Marcel-Decker Inc, New York, Basel, Hong-Kong.
7. Ghan G.A., Lalla J.K. Effect of compressional forces on piroxicam polymorphs. J. Pharm. Pharmacol. 44:1992;678-681.
8. Pirttimäki J., Laine E., Ketolainen J., Paronen P. Effects of grinding and compression on crystal structure of anhydrous caffeine. Int. J. Pharm. 95:1993;93-99.
9. Otsuka M., Otsuka K., Kaneniwa N. Relation between polymorphic transformation pathway during grinding and the physicochemical properties of bulk powders for pharmaceutical preparations. Drug Dev. Ind. Pharm. 20:(9):1994;1649-1660.
10. Hellemann M., Griesser U.J., Abberger T., Schlocker W., Burger A. Phase purity and impact of polymorphism on the material properties of caffeine. PharmSci. 2:(4):2000;3091.
11. Hancock B.C., Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm. Res. 17:(4):2000;397-404.
12. Hüttenrauch R. Molekulargalenik als Grundlage moderner Arzneiformung. Acta. Pharm. Technol. 6:1978;55-127.
13. Picker K.M. Influence of tableting on the enzymatic activity of different α-amylases by using various excipients. Eur. J. Pharm. Biopharm. 53:2002;181-185.
14. Picker K.M. Matrix tablets of carrageenans I. a compaction study. Drug Dev. Ind. Pharm. 25:(3):1999;329-337.
15. Picker K.M. The use of carrageenan in mixture with microcrystalline cellulose and its functionality for making tablets. Eur. J. Pharm. Biopharm. 48:1999;27-36.
16. Yamamoto H. 1-Acyl-indoles. II A new synthesis of 1-(p-chlorobenzoyl)-5-methoxy-3-indolylacid and its polymorphism. Chem. Pharm. Bull. 16:1968;17-19.
17. Pakula R., Pichnej L., Spychala S., Butkiewicz K. Polymorphism of indomethacin Part I. Preparation of polymorphic forms of indomethacin. Pol. J. Pharmacol. Pharm. 29:1977;151-156.
18. Spychala S., Butkiewicz K., Pakula R., Pichnej L. Polymorphism of indomethacin Part II. identification and rapid determination of polymorphic forms of indomethacin by IR spectrometry. Pol. J. Pharmacol. Pharm. 29:1977;157-161.
19. Lin S.-Y. Isolation and solid-state characteristics of a new crystal form of indomethacin. J. Pharm. Sci. 81:(6):1992;572-576.
20. Yoshioka M., Hancock B.C., Zografi G. Crystallization of indomethacin from the amorphous state below and above its glass transition temperature. J. Pharm. Sci. 83:(12):1994;1700-1705.
21. Davies M.C., Binns J.S., Melia C.D., Hendra P.J., Bourgeois D., Church S.P. FT-Raman spectroscopy of drugs in polymers. Int. J. Pharm. 66:1990;223-232.
22. Taylor L.S., Zografi G. The quantitative analysis of crystallinity using FT-Raman spectroscopy. Pharm. Res. 15:(5):1998;755-761.
23. Taylor L.S., Langkilde F.W. Evaluation of solid-state forms present in tablets by Raman-spectroscopy. J. Pharm. Sci. 89:(10):2000;1342-1353.
24. Matsumoto T., Zografi G. Physical properities of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinylacetate) in relation to indomethacin crystallisation. Pharm. Res. 16:(11):1999;1722-1728.
25. Yoshioka M., Hancock B.C., Zografi G. Inhibition of indomethacin crystallization in poly(vinylpyrrolidone) coprecipitates. J. Pharm. Sci. 84:(8):1995;983-986.
26. G. Zessin, Untersuchungen zur Arzneistofffreigabe aus Matrixtabletten und deren Beeinflussung am Beispiel eines Antasthmatikums, Habilitationsschrift, Universität Halle-Wittenberg, 1976.
27. Picker K.M. Time dependence of elastic recovery of characterization of tableting materials. Pharm. Dev. Technol. 6:2001;61-70.
28. Taylor L.S., Zografi G. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm. Res. 14:(12):1997;1691-1698.
29. Heckel R.W. Density-pressure relationships in powder compaction. Trans. Metal. Soc. AIME. 221:(8):1961;671-675.
30. Heckel R.W. An analysis of powder compaction phenomena. Trans. Metal. Soc. AIME. 221:(10):1961;1001-1008.
31. Picker K.M. A new theoretical model to characterize the densification behavior of tableting materials. Eur. J. Pharm. Biopharm. 49:2000;267-273.
32. Kontoyannis C.G., Bouropoulos N.C., Koutsoukos P.G. Use of Raman spectroscopy for the quantitative analysis of calcium oxalate hydrate: applications for the analysis of urinary stones. Appl. Spectrosc. 51:(1):1997;64-67.
33. Andronis V., Yoshioka M., Zografi G. Effects of sorbed water on the crystallization of indomethacin from the amorphous state. J. Pharm. Sci. 86:(3):1997;346-351.
34. Otsuka M., Matsumoto T., Kaneniwa N. Effect of environmental temperature on polymorphic solid-state transformation of indomethacin during grinding. Chem. Pharm. Bull. 34:(4):1986;1784-1793.
35. Andronis V., Zografi G. The molecular mobility of supercooled amorphous indomethacin as a function of temperature and relative humidity. Pharm. Res. 15:(6):1998;835-843.
36. Phadnis N.V., Suryanarayanan R. Polymorphism in anhydrous theophylline-implications on the dissolution rate of theophylline tablets. J. Pharm. Sci. 86:(11):1997;1256-1263.
37. Suihko E., Ketolainen J., Poso A., Ahlgren M., Gynther J., Paronen P. Dehydration of theophylline monohydrate-a two step process. Int. J. Pharm. 158:1997;47-55.
38. Suzuki E., Shimomura K., Sekiguchi K. Thermochemical study of theophylline and its hydrate. Chem. Pharm. Bull. 37:(2):1989;493-497.
39. Shefter E., Fung H.-L. Dehydration of crystalline theophylline monohydrate and ampicillin trihydrate. J. Pharm. Sci. 62:(5):1973;791-794.
40. Agbade C.O., York P. Dehydration of theophylline monohydrate - effects of particle size and sample weight. Int. J. Pharm. 106:1994;33-40.
41. Otsuka M., Kaneniwa N. The dehydration kinetics of theophylline monohydrate - powder and tablet. Chem. Pharm. Bull. 36:(12):1988;4914-4920.